Page 425 - Read Online

Page 13 of 36 J Cancer Metastasis Treat 2019;5:31 I http://dx.doi.org/10.20517/2394-4722.2019.21

AF cells were injected subcutaneously into CD nu/nu mice and tumor masses were evident after 20 days.
Tumor growth was significantly inhibited by lenvatinib (25 mg/kg/day), as the VEGF-A expression and
microvessel density in AF tumor tissues.

In conclusion, we show for the first time the antitumoral effect of lenvatinib in primary human ATC cell
cultures obtained from patients. These results could open the way to the clinical use of lenvatinib in the
treatment of patients with ATC.

Biography
Prof. Antonelli is currently Director of the Immuno-Endocrine Section of Internal Medicine and
Associate Professor in the Department of Clinical and Experimental Medicine, University of Pisa, Azienda
Ospedaliera-Universitaria Pisana, Pisa, Italy.

He graduated in Medicine cum laude at the University of Pisa in 1982, where he received the post-graduate
Specialization in Endocrinology in 1985 and in Occupational Health in 1987. He received also the post-
graduate Specialization in Oncology (at the University La Sapienza, Rome, Italy) in 1992.

His researches have been published in more than 320 articles on International journals (Impact Factor >
1200; H index 60).

17. Novel inducers of noncanonical and immunogenic cell death

Marc Diederich

Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul 151742, South Korea.

Apoptosis was most often considered as the most important type of cell death and numerous compounds
triggering this programmed form of cell demise were explored. Over the last 10 years, other cell death
modalities were also described, and proof of concept was provided that such compounds are efficiently
able to target cancer cells that already became resistant to conventional apoptosis inducers. Moreover,
[1]
the interplay between different cell death modalities gained interest . We became interested to assess
the anticancer effect of compounds that were shown to kill cells by triggering various necrosis-related
[2,3]
phenotypes . We believe that these compounds provide a more efficient therapeutic outcome. For our
research we essentially investigated compounds of natural origins from both marine [4-6] and terrestrial
sources [7-10] . Multiple forms of regulated necrosis and the in-depth elucidation of the corresponding cell
signaling pathways allowed to better predict the immunogenic potential of cancer cells dying by non-
canonical cell death mechanisms [11-13] . This presentation will cover the effect of various natural and
hemisynthetic compounds while describing their cell death-inducing activity leading to secretion or
exposure of immunogenic cell death markers [14-16] .

REFERENCES
1. Radogna F, Dicato M, Diederich M. Cancer-type-specific crosstalk between autophagy, necroptosis and apoptosis as a pharmacological
target. Biochem Pharmacol 2015;94:1-11.
2. Florean C, Song S, Dicato M, Diederich M. Redox biology of regulated cell death in cancer: a focus on necroptosis and ferroptosis. Free
Radic Biol Med 2019;134:77-189.
3. Diederich M, Cerella C. Non-canonical programmed cell death mechanisms triggered by natural compounds. Semin Cancer Biol
2016;40-41:4-34.
4. Lee JY, Orlikova B, Diederich M. Signal transducers and activators of transcription (STAT) regulatory networks in marine organisms:
from physiological observations towards marine drug discovery. Mar Drugs 2015;13:4967-84.